staurosporine has been researched along with harmine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jarhad, DB; Jeong, LS; Kim, HR; Mashelkar, KK; Noh, M | 1 |
| Abadi, AH; Abdel-Halim, M; Becker, W; Darwish, SS; Engel, M; Salah, M | 1 |
| Chen, H; Ding, H; Gao, Y; Jiang, X; Liu, W; Liu, X; Tian, L; Xu, Z; Zhao, Q | 1 |
| Chen, H; Gao, Y; Huang, Y; Jiang, X; Li, D; Liu, W; Liu, X; Wang, N; Wu, L; Xu, Z; Zhao, Q; Zhou, L | 1 |
1 review(s) available for staurosporine and harmine
| Article | Year |
|---|---|
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
Topics: Animals; Biological Products; Disease; Dyrk Kinases; Enzyme Activation; Humans; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases | 2018 |
3 other study(ies) available for staurosporine and harmine
| Article | Year |
|---|---|
Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives.
Topics: Amides; Benzamides; Dose-Response Relationship, Drug; Dyrk Kinases; Humans; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship; Thiophenes | 2018 |
Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Dyrk Kinases; Glycogen Synthase Kinase 3 beta; Harmine; Humans; Models, Molecular; Molecular Structure; Neuroprotective Agents; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship | 2021 |
Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Antineoplastic Agents; Apoptosis; Carbolines; Cell Line, Tumor; Cell Proliferation; Cholinesterase Inhibitors; Drug Design; Glycogen Synthase Kinase 3 beta; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Protein Kinase Inhibitors; Signal Transduction; Structure-Activity Relationship | 2022 |